ReciBioPharm to Develop And Manufacture AAV Therapies Using NewBiologix’s Xcell-Eng-HEK293 Cell Line

NewBiologix, a technology innovation company specializing in scalable and cost-effective solutions for viral vector production in cell and gene therapy (C\&GT), has announced a non-exclusive technology licensing agreement with ReciBioPharm, the advanced therapies division of Recipharm. Through this agreement, ReciBioPharm, a leading Contract Development and Manufacturing Organization (CDMO), will now be able to offer global biotech and pharmaceutical companies access to NewBiologix’s Xcell-Eng-HEK293 cell lines.

The Xcell-Eng-HEK293 cell lines are designed to improve the manufacturing of recombinant adeno-associated viruses (rAAV), which are widely used in the development of gene therapies. These cell lines are optimized for high yields and consistent viral particle production and are available in a cGMP-ready format, helping companies accelerate development timelines and move more efficiently into clinical trials. NewBiologix’s platform combines advanced digital PCR and third-generation sequencing to create tightly controlled and highly productive cell lines.

By integrating NewBiologix’s cell lines into its AAV manufacturing processes, ReciBioPharm has achieved significant performance results across various gene therapy programs. The company consistently produces yields exceeding 2E15 viral genomes per liter, even when working with large gene constructs. Its manufacturing approach also delivers more than 95% full capsids in final formulations, ensuring high product quality and efficacy.

Igor Fisch, CEO and co-founder of NewBiologix, said in a statement, “Our ambition is to become the leading company for providing solutions for gene therapies, based on Swiss engineering and precision. Our technology licensing agreement for ReciBioPharm, a global leader in ATMP development and manufacturing, will help ensure patients benefit from life-saving treatments through economically viable, large-scale production of viral vectors. Core to this offering is our Xcell-Eng-HEK293 cell line, complemented with advanced analytics to guarantee the highest quality AAV for transformative therapeutic solutions. We’re not just advancing gene therapy; we’re redefining how it’s built."

Vikas Gupta, President of ReciBioPharm, mentioned, “Our strategic collaborations and technology advancements in 2024 reaffirmed our commitment to being a trusted partner in ATMPs. Our technology licensing agreement with NewBiologix for the Xcell-Eng-HEK293 cell line strengthens our position in the AAV space. Together, we advance the needs of our customers by driving down the costs of developing and manufacturing high quality AAV therapies.”

ReciBioPharm has successfully validated the use of these cell lines in producing over 10 different rAAV serotypes, enabling support for a wide range of therapeutic applications. Its end-to-end offering—from research-grade production to GMP manufacturing—ensures a streamlined, scalable path for therapy developers from early-stage research through commercialization.

Last year, NewBiologix introduced its Xcell™ Portfolio, a collection of advanced tools and technologies aimed at improving rAAV quality and consistency. This portfolio integrates NewBiologix’s proprietary HEK293 cell lines with production and analytical solutions, helping gene therapy developers overcome ongoing challenges in the field. The collaboration with ReciBioPharm represents another step forward in making safer, more effective gene therapies accessible to patients worldwide.